Diabetic Foot Disorders: A Clinical Practice Guideline

of 68

Please download to get full document.

View again

All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
68 pages
0 downs
SEPTEMBER/OCTOBER 2006 VOLUME 45, NUMBER 5 A Supplement to: The Journal of Foot & Ankle Surgery DIABETIC FOOT DISORDERS A CLINICAL PRACTICE GUIDELINE Development and publication of this Clinical Practice Guideline was made possible by an Educational Grant Co-Sponsored by Johnson & Johnson Wound Management, a division of ETHICON, INC. and KCI USA, Inc. An official publication of the American College of Foot and Ankle Surgeons Supplement to: The Journal of Foot & An k l e Surgery DIABETIC FOOT DISORDERS: A CLINICAL PRACTICE GUIDELINE (2006 revision) Robert G. Frykberg, DPM, MPH,1 Thomas Zgonis, DPM,2 David G. Armstrong, DPM, PhD,3 Vickie R. Driver, DPM, MS4 John M. Giurini, DPM,5 Steven R. Kravitz, DPM,6 Adam S. Landsman, DPM, PhD,7 Lawrence A. Lavery, DPM, MPH,8 J. Christopher Moore, DPM,9 John M. Schuberth, DPM,10 Dane K. Wukich, MD,11 Charles Andersen, MD,12 and John V. Vanore, DPM13 Address correspondence to: Robert G. Frykberg, DPM, MPH, Chief, Podiatric Surgery, Carl T. Hayden VA Medical Center, Phoenix, AZ 85012. Email: a class= __cf_email__ href= /cdn-cgi/l/email-protection data-cfemail= f3819c91968187dd95818a9891968194b39e9697dd8592dd949c85 [email protected] /a script data-cfhash='f9e31' type= text/javascript /* ![CDATA[ */!function(t,e,r,n,c,a,p){try{t=document.currentScript||function(){for(t=document.getElementsByTagName('script'),e=t.length;e--;)if(t[e].getAttribute('data-cfhash'))return t[e]}();if(t&&(c=t.previousSibling)){p=t.parentNode;if(a=c.getAttribute('data-cfemail')){for(e='',r='0x'+a.substr(0,2)|0,n=2;a.length-n;n+=2)e+='%'+('0'+('0x'+a.substr(n,2)^r).toString(16)).slice(-2);p.replaceChild(document.createTextNode(decodeURIComponent(e)),c)}p.removeChild(t)}}catch(u){}}()/* ]] */ /script 1Chair, Diabetes Panel, Phoenix, AZ; 2 San Antonio, TX; 3 North Chicago, IL; 4 Evanston, IL; 5 Boston, MA; 6 Richboro, PA; 7 Boston, MA; 8 Georgetown, TX; 9 Ashville, NC; 10 San Francisco, CA; 11 Pittsburgh, PA; 12 Seattle, WA; 13 Chair, Clinical Practice Guidelines Core Committee, Gadsden, AL The Journal of Foot & An k l e Surgery Supplement to: DIABETIC FOOT DISORDERS: A CLINICAL PRACTICE GUIDELINE (2006 revision) ABSTRACT: The prevalence of diabetes mellitus is growing at epidemic proportions in the United States and worldwide. Most alarming is the steady increase in type 2 diabetes, especially among young and obese people. An estimated 7% of the US population has diabetes, and because of the increased longevity of this population, diabetes-associated complications are expected to rise in prevalence. Foot ulcerations, infections, Charcot neuroarthropathy, and peripheral arterial disease frequently result in gangrene and lower limb amputation. Consequently, foot disorders are leading causes of hospitalization for persons with diabetes and account for billion-dollar expenditures annually in the US. Although not all foot complications can be prevented, dramatic reductions in frequency have been achieved by taking a multidisciplinary approach to patient management. Using this concept, the authors present a clinical practice guideline for diabetic foot disorders based on currently available evidence, committee consensus, and current clinical practice. The pathophysiology and treatment of diabetic foot ulcers, infections, and the diabetic Charcot foot are reviewed. While these guidelines cannot and should not dictate the care of all affected patients, they provide evidence-based guidance for general patterns of practice. If these concepts are embraced and incorporated into patient management protocols, a major reduction in diabetic limb amputations is certainly an attainable goal. This clinical practice guideline (CPG) is based on the consensus of current clinical practice and review of the clinical literature. This guideline was developed by the Clinical Practice Guideline Diabetes Panel of the American College of Foot and Ankle Surgeons. INTRODUCTION The prevalence of diabetes mellitus is growing at epidemic proportions in the United States and worldwide (1). Most alarming is the steady increase in type 2 diabetes, especially among young and obese persons. An estimated 7% of Americans are afflicted with diabetes, and with the longevity of this population increasing, the prevalence of diabetesrelated complications will continue to rise. Foot disorders are a major source of morbidity and a leading cause of hospitalization for persons with diabetes. Ulceration, infection, gangrene, and amputation are significant complications of the disease, estimated to cost billions of dollars each year. Charcot foot, which of itself can lead to limb-threatening disorders, is another serious complication of long-standing diabetes. In addition to improving the management of ulcers—the leading precursor to lower extremity amputation in diabetic patients (2)—clinicians S–2 THE JOURNAL OF FOOT & ANKLE SURGERY must determine how to more effectively prevent ulceration. Although not all diabetic foot disorders can be prevented, it is possible to effect dramatic reductions in their incidence and morbidity through appropriate evidence-based prevention and management protocols. Taking a multidisciplinary approach to diabetic foot disorders, many centers from around the world have noted consistent improvement in limb salvage rates. With this premise as our central theme, the authors present this clinical practice guideline based on currently available evidence. Three major pedal complications of diabetes are reviewed: diabetic foot ulcers, diabetic foot infections, and the diabetic Charcot foot. These guidelines are intended to provide evidence-based guidance for general patterns of practice and do not necessarily dictate the care of a particular patient. EPIDEMIOLOGY OF DIABETIC FOOT DISORDERS Diabetes is one of the foremost causes of death in many countries and a leading cause of blindness, renal failure, and nontraumatic amputation. Global prevalence of diabetes in 2003 was estimated to be 194 million (3). By 2030, this figure is predicted to rise to 366 million due to longer life expectancy and changing dietary habits (4). The estimated incidence of diabetes in the US exceeds 1.5 million new cases annually, with an overall prevalence of 20.8 million people or 7% of the nation’s population (5). An estimated 14.6 million persons are currently diagnosed with the disease, while an additional 6.2 million people who have diabetes remain undiagnosed; this represents a sixfold increase in the number of persons with diabetes over the past four decades (6). A higher incidence of diabetes occurs among non-Hispanic blacks, Hispanic/Latino Americans, and Native Americans compared with non-Hispanic whites (7). Diagnosed diabetes is most prevalent in middle-aged and elderly populations, with the highest rates occurring in persons aged 65 years and older (8-10). As the sixth leading cause of death in the US, diabetes contributes to more than 224,000 deaths per year (5). among patients with diabetes (9, 12). Rates of heart disease and stroke are 2 to 4 times higher among diabetic adults compared with nondiabetic adults, accounting for about 65% of deaths in people with diabetes (5). Estimated total (direct and indirect) annual expenditures for diabetes management in 2002 was $132 billion, representing 1 of every 10 health care dollars spent in the US (13). One of the most common complications of diabetes in the lower extremity is the diabetic foot ulcer. An estimated 15% of patients with diabetes will develop a lower extremity ulcer during the course of their disease (14-17). Several population-based studies indicate a 0.5% to 3% annual cumulative incidence of diabetic foot ulcers (18-21). According to one large British study of neuropathic patients, the 1-year incidence of initial foot ulcer was 7% (22). The prevalence of foot ulcers reported for a variety of populations ranges from 2% to 10% (16, 18, 22, 23). Neuropathy, deformity, high plantar pressure, poor glucose control, duration of diabetes, and male gender are all contributory factors for foot ulceration (see the following section: “Risk for Ulceration”) (24-27). National hospital discharge data indicate that the average hospital length of stay (LOS) for diabetic patients with ulcer diagnoses was 59% longer than for diabetic patients without ulcers (16). While 7% to 20% of patients with foot ulcers will subsequently Table 1 Classification of Diabetes Mellitus * require an amputation, foot ulceration is the precursor to Type 1 diabetes - absolute insulin deficiency approximately 85% of lower extremity of amputations in Type 2 diabetes - insulin resistant +/- insulin deficiency Other types - genetic defects of ß-cell function or insulin action persons with diabetes (28-31). endocrinopathies Diabetes continues to be the most common underlying drug or chemical cause of nontraumatic lower extremity amputations (LEAs) infections in the US and Europe (1, 32). More than 60% of LEAs in Gestational diabetes the US occur in people with diabetes, averaging 82,000 per * adapted from: Therapy for Diabetes Mellitus and Related Disorders, 3rd edition, American Diabetes Association, 1998. year (5, 10). While the number of diabetes-related hospital discharges has progressively increased from 33,000 in 1980 to 84,000 in 1997, this number seems to have leveled off Four categories of diabetes are recognized (Table 1). Type during the present decade. In 2002, there were 82,000 dia1, formerly insulin-dependent diabetes mellitus (IDDM), is betes-related LEA discharges, accounting for 911,000 days an autoimmune disease affecting the pancreas. Individuals of hospital stay with an average LOS of 11.2 days (10). The with type 1 diabetes are prone to ketosis and unable to proage-adjusted rate of amputation for that year was 5.2 per duce endogenous insulin. Type 2, formerly non-insulin 1,000 persons with diabetes, a notable decrease from the dependent diabetes mellitus (NIDDM), accounts for 90% to highest rate of 8.1 per 1,000 in 1996. 95% of cases diagnosed. Type 2 diabetes is characterized by In terms of level of diabetes-related lower limb amputahyperglycemia in the presence of hyperinsulinemia due to tions, toe amputations comprise the majority of procedures. peripheral insulin resistance. Gestational as well as genetic The age-adjusted LEA rate in 2002 among persons with diadefects and endocrinopathies are recognized as other types betes was highest for toe LEA (2.6 per 1,000 persons), folof diabetes (11). Diabetes is associated with numerous lowed by below-knee LEA (1.6 per 1,000 persons). For foot complications related to microvascular, macrovascular, and LEA and above-knee LEA, the age-adjusted rate was 0.8 metabolic etiologies. These include cerebrovascular, cardioper 1,000 persons. These trends in amputation level have vascular, and peripheral arterial disease; retinopathy; neuessentially remained the same since 1993 (10). Generally, ropathy; and nephropathy. Currently, cardiovascular comthe LEA rate is 15 to 40 times higher in the diabetic versus plications are the most common cause of premature death DIABETIC FOOT DISORDERS VOLUME 45, NUMBER 5, SEPTEMBER/OCTOBER 2006 S–3 nondiabetic populations, and the rate is at least 50% higher in men versus women (8, 10, 12, 33). In 2002, the ageadjusted LEA rate among men was 7.0 per 1,000 persons with diabetes compared with to the rate among women reported at 3.3 per 1000 persons with diabetes (10). Several ethnic differences occur in the frequency of diabetes-related amputations. Mexican (Hispanic) Americans, Native Americans, and African Americans each have at least a 1.5- to 2-fold greater risk for diabetes-related amputation than age-matched diabetic Caucasians (8, 10, 16, 17, 34, 35). When LEA risk is compared between diabetic and nondiabetic populations worldwide, it is apparent that both diabetes and ethnicity have profound implications on rates of lower limb amputation (1, 17). Survival rates after amputation are generally lower for diabetic versus nondiabetic patients (16, 17, 29). The 3- and 5-year survival rates are about 50% and 40%, respectively, with cardiovascular disease being the major cause of death (8). Although mortality rates following major amputation are high among both diabetic and nondiabetic patients, a recent study reported no significant difference between these two populations. The mean survival was approximately 6.5 years, with a 68% mortality after 9 years regardless of diabetes status (36). An earlier study from Sweden reported a 5-year mortality rate of 68% after lower limb amputation, with survival rates lower among patients who underwent higher levels of amputation (29). Similar trends were found in a review of amputations within the Veterans Affairs system, but worse survival outcomes were observed for older patients, those with renal disease, and those with peripheral arterial disease (37). Researchers have reported a 50% incidence of serious contralateral foot lesion (ie, ulcer) following an LEA, and a 50% incidence of contralateral amputation within 2 to 5 years of an LEA (16, 29). Total (direct and indirect) annual health care costs for persons with diabetes were estimated to be $132 billion in 2002. Direct medical expenditures, including hospitalization, medical care, and supplies, accounted for $91.8 billion (13). The estimated cost for foot ulcer care in the US ranges from $4,595 per ulcer episode to nearly $28,000 for the 2 years after diagnosis (19, 38). One report estimates 800,000 prevalent ulcer cases in the US, with costs averaging $5,457 per year per patient or total national annual costs of $5 billion (39). A study of Medicare claims data found that expenditures for patients with lower extremity ulcers averaged 3 times higher than expenditures for Medicare beneficiaries in general. With 24% of their total costs allocated to ulcerrelated expenses, lower extremity ulcer patients cost the Medicare system $1.5 billion in 1995 (40). According to a large prospective study of diabetic patients with foot ulcers, S–4 THE JOURNAL OF FOOT & ANKLE SURGERY about 7% will subsequently require a lower extremity amputation (31). While hospital LOSs for diabetes-related LEA have progressively decreased in the US, the overall direct costs remain high (10, 16). Direct and indirect costs of LEA—which range from $20,000 to $40,000 per event— vary by year, payer, level of amputation, LOS, and attendant comorbidities (16). If the lower figure is applied to the 82,000 amputations performed in 2002, estimated total costs of LEA might exceed $1.6 billion annually. When outpatient costs for ulcer care preceding these amputations is added, the estimated total costs in the US for diabetic foot disease can easily approach or exceed $6 billion annually. Risk for Ulceration Foot ulceration is the most common single precursor to lower extremity amputations among persons with diabetes (28-30). Treatment of infected foot wounds comprises up to one quarter of all diabetic hospital admissions in the US and Britain, making this the most common reason for diabetesrelated hospitalization in these countries (41-43). The multifactorial nature of diabetic foot ulceration has been elucidated by numerous observational studies (16, 22, 24, 26, 27, 44-48). Risk factors identified include peripheral neuropathy, vascular disease, limited joint mobility, foot deformities, abnormal foot pressures, minor trauma, a history of ulceration or amputation, and impaired visual acuity (25, 49, 50). These and other putative causative factors are shown in Figure 1. Peripheral sensory neuropathy in the face of unperceived trauma is the primary factor leading to diabetic foot ulcerations (24, 27, 46, 49). Approximately 45% to 60% of all diabetic ulcerations are purely neuropathic, while up to 45% have neuropathic and ischemic components (24, 51). According to an important prospective multicenter study, sensory neuropathy was the most frequent component in the causal sequence to ulceration in diabetic patients (24). Other forms of neuropathy may also play a role in foot ulceration. Motor neuropathy resulting in anterior crural muscle atrophy or intrinsic muscle wasting can lead to foot deformities such as foot drop, equinus, hammertoe, and prominent plantar metatarsal heads (25, 26, 52-54). Ankle equinus with restricted dorsiflexory range of motion is fairly common in patients with diabetic neuropathy and can be a consequence of anterior crural muscle atrophy (55-60). The decreased ankle motion, which confers higher-thannormal plantar pressures at the forefoot, has been implicated as a contributory cause of ulceration as well as recurrence or recalcitrance of existing ulcers (57, 58, 60, 61). Autonomic neuropathy often results in dry skin with cracking and fissuring, creating a portal of entry for bacte- Figure 1 The risk factors for ulceration may be distinguished by general or systemic considerations versus those localized to the foot and its pathology. ria (42, 63). Autosympathectomy with attendant sympathetic failure, arteriovenous shunting, and microvascular thermoregulatory dysfunction impairs normal tissue perfusion and microvascular responses to injury. These alterations can subsequently be implicated in the pathogenesis of ulceration (63-67). Foot deformities resulting from neuropathy, abnormal biomechanics, congenital disorders, or prior surgical intervention may result in high focal foot pressures and increased risk of ulceration (24, 48, 50, 57, 68-71). The effects of motor neuropathy occur relatively early and lead to foot muscle atrophy with consequent development of hammertoes, fat pad displacement, and associated increases in plantar forefoot pressures (53, 72-75). Although most deformities cause high plantar pressures and plantar foot ulcerations, medial and dorsal ulcerations may develop as a result of footwear irritation. Common deformities might include prior partial foot amputations, prominent metatarsal heads, hammertoes, Charcot arthropathy, or hallux valgus (69, 76-79). A large prospective population-based study found that elevated plantar foot pressures are significantly associated with neuropathic ulceration and amputation (80). The study also revealed a trend for increased foot pressures as the number of pedal deformities increased. Trauma to the foot in the presence of sensory neuropathy is an important component cause of ulceration (24). While trauma may include puncture wounds and blunt injury, a common injury leading to ulceration is moderate repetitive stress associated with walking or day-to-day activity (69, 76, 81). This is often manifested by callus formation under the metatarsal heads (48, 82, 83). A recent report suggests that even with moderate activity, ulceration may be precipitated by a higher degree of variability in activity or periodic “bursts” of activity (84). Shoe-related trauma has also been identified as a frequent precursor to foot ulceration (28, 51, 54, 85, 86). Peripheral arterial disease (PAD) rarely leads to foot ulcerations directly. However, once ulceration develops, arterial insufficiency will result in prolonged healing, imparting an elevated risk of amputation (28, 87, 88). Additionally, attempts to resolve any infection will be impaired due to lack of oxygenation and difficulty in delivering antibiotics to the infection site. Therefore, early recognition and aggressive treatment of lower extremity ischemia are vital to lower limb salvage (30, 52, 89-91). Limited joint mobility has also been described as a potential risk factor for ulceration (92-94). Glycosylation of collagen as a result of longstanding diabetes may lead to stiffening of capsular structures and ligaments (cheiroarthropathy) (95). The subsequent reduction in ankle, subtalar, and first metatarsophalangeal (MTP) joint mobility has been shown to result in high focal plantar pressures with increased ulceration risk in patie
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks